Biogen | BIIB - Operating Expenses


Biogen reported $1.88B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Amgen USD 5.9B 773M Dec/2025
Bayer EUR 10.2B 523M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 1.21B Dec/2025
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025